PL445561A1 - Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet - Google Patents

Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet

Info

Publication number
PL445561A1
PL445561A1 PL445561A PL44556123A PL445561A1 PL 445561 A1 PL445561 A1 PL 445561A1 PL 445561 A PL445561 A PL 445561A PL 44556123 A PL44556123 A PL 44556123A PL 445561 A1 PL445561 A1 PL 445561A1
Authority
PL
Poland
Prior art keywords
women
blood lead
whole blood
lead concentration
optimizing whole
Prior art date
Application number
PL445561A
Other languages
English (en)
Inventor
Jan LUBIŃSKI
Ewa Siwiec
Róża Derkacz
Wojciech MARCINIAK
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL445561A priority Critical patent/PL445561A1/pl
Publication of PL445561A1 publication Critical patent/PL445561A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób obniżania niskich (<20 µg/l) stężeń ołowiu we krwi, polega on na tym, że obejmuje suplementację DMSA w dawce 10 mg/kg masy ciała/dzień co skutkuje obniżeniem o ponad 50% poziomu ołowiu we krwi u kobiet już po 4 tygodniach.
PL445561A 2023-07-12 2023-07-12 Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet PL445561A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445561A PL445561A1 (pl) 2023-07-12 2023-07-12 Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445561A PL445561A1 (pl) 2023-07-12 2023-07-12 Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet

Publications (1)

Publication Number Publication Date
PL445561A1 true PL445561A1 (pl) 2025-01-13

Family

ID=94177721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445561A PL445561A1 (pl) 2023-07-12 2023-07-12 Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet

Country Status (1)

Country Link
PL (1) PL445561A1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041657A1 (en) * 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041657A1 (en) * 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRACIA, R.C. ET AL.: "American Journal of Health-System Pharmacy, Volume 64, Issue 1, 1 January 2007, Pages 45–53", „LEAD TOXICITY AND CHELATION THERAPY" *
SAMPLE, J.A.: "9-01-2024, publikacja dostępna pod adresem https://medilib.ir/uptodate/show/6494", „CHILDHOOD LEAD POISONING: MANAGEMENT" *
SHRODER, A.P. ET AL.: "US Pharm. 2015; 40(5):40-44", "LEAD TOXICITY AND CHELATION THERAPY" *

Similar Documents

Publication Publication Date Title
MX2023000589A (es) Terapia de combinacion para tratar el crecimiento celular anormal.
JOP20200169A1 (ar) تركيبة لمنع الحمل بتأثيرات منخفضة على القلب والأوعية
AR109995A2 (es) Método para inhibir la resorción ósea
Drewnoski et al. Ferric citrate decreases ruminal hydrogen sulphide concentrations in feedlot cattle fed diets high in sulphate
MX2024011403A (es) Tratamiento con mirdametinib.
PL445561A1 (pl) Sposób optymalizacji stężenia ołowiu we krwi pełnej u kobiet
PH12022550753A1 (en) A mesenchymal stem cell storing or transport formulation and methods of making and using the same
Callejo et al. Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension
Spinnato et al. Prevention of preeclampsia with antioxidants: evidence from randomized trials
PH12021553055A1 (en) Methods and compositions for improving outcomes of cancer patients
BR112021022208A2 (pt) Métodos para tratamento de distrofia muscular usando oligonucleotídeos inibidores para cd49d
Ibrahim et al. Effect of selenium and zinc supplementation on hypothyroidism in rats
Jelodar et al. Arginase alteration in the reproductive system of alloxan-diabetic dogs
PH12020551330A1 (en) Insecticidal composition and use thereof
WO2024073420A3 (en) Administration of glutathione trisulfide to ameliorate peripheral neuropathy
Gaulden et al. Micronutrients in congestive heart failure: an integrative review
Noah et al. Effect of vitamin B6 supplementation, in combination with magnesium, on severe stress and magnesium status: secondary analysis from an RCT
Kawata et al. Breeding severely vitamin B12-deficient mice as model animals
UA158367U (uk) Спосіб одержання композиції для лікування носа у формі мазі
Hulter et al. Chronic hyperkalemic renal tubular acidosis induced by KCl loading
PL427987A1 (pl) Sposób modyfikacji stężenia arsenu
Bouillon et al. Vitamin D and the skeleton
Prince Calcium and vitamin D–for whom and when
Pettigrew et al. Red cell glutathione in tobacco amblyopia
Ramesh THE EFFECT OF IRON REPLACEMENT THERAPY ON HYPOTHYROID PATIENTS WITH IRON DEFECIENCY ANEMIA